[Policy Recommendations] Improving Patient Access to Genomic Cancer Medicine (August 10, 2023)
date : 8/10/2023
Tags: NCDs, Precision Cancer Medicine
![[Policy Recommendations] Improving Patient Access to Genomic Cancer Medicine (August 10, 2023)](https://hgpi.org/en/wp-content/uploads/sites/2/ncd-20230810-figure1_ENG.jpg)
Health and Global Policy Institute (HGPI) has presented a policy recommendation paper regarding the improvement of patient access to Genomic Cancer Medicine.
Executive summary
- Genomic Cancer Medicine was viewed as an advanced form of medical treatment when Comprehensive Genomic Profiling (CGP; or cancer gene panel tests) was granted health insurance coverage in 2019. Since then, people serving in clinical settings have accumulated experience handling this form of treatment. We are now at a stage to make Genomic Cancer Medicine a form of technology from which anyone should be able to benefit. To achieve this, we should improve patient access to deliver Genomic Cancer Medicine more broadly to the public.
- From the perspective of patient access opportunities, policy challenges with respect to delivering Genomic Cancer Medicine may be sorted into three categories:
A: Constraints related to human resources in medicine
B: Constraints related to genetic testing
C: Constraints related to geographic factors or information
We must take wherever possible actions to address each issue one by one, and expand opportunities for patients to access Genomic Cancer Medicine.
- Based on these understandings, HGPI offers the following recommendations:
RECOMMENDATION I: Streamline operations and secure human resources
In view of the further spread of genomic cancer medicine, streamline operations thoroughly, and adopt systems to secure human resources commensurate with workloads.
RECOMMENDATION II: Review genetic testing practices including how tests are performed
Based on the accumulated clinical experiences, revise the genetic tests and related practices to meet the needs of those serving in clinical settings, and to suit the characteristics of each type of cancer.
RECOMMENDATION III: Improve patient access to testing centers and clinical trials
While paying attention to the constraints and disparities related to geographic factors/information, make drastic improvements to patient access to testing centers and clinical trials.
As for precision cancer medicine, HGPI launched an initiative in FY2021 (“Project for Considering the Future of Precision Medicine with Industry, Government, Academia, and Civil Society”), and has made expert hearings and conducted surveys to examine the issue. Based on our findings, we offered comprehensive policy recommendations in September 2022.
For the second phase of this project, we compiled this policy recommendation paper, based on additional, expansive surveys and hearings with our focus on measures for better patient access to Genomic Cancer Medicine.
HGPI strongly hopes these recommendations will be utilized in developing further policy measures for Genomic Cancer Medicine, and patient-centered healthcare.
For details, please see the PDFs linked below.
Sponsors (in alphabetical order):
Bayer Yakuhin, Ltd.
Chugai Pharmaceutical Co., Ltd.
Janssen Pharmaceutical K.K.
MSD K.K.
Top Research & Recommendations Posts
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Research Paper] “Rethinking Japan’s Health System Sustainability Under the Planetary Health Framework” Published in Health Systems & Reform (November 21, 2023)
- [Announcement] HGPI Joins Call for “Global Health and Medical Community Unite To Demand End Fossil Fuel Dependency at COP28” (November 1, 2023)
- [Research Report] The Public Opinion Survey on Child-Rearing in Modern Japan (Final Report) (March 4, 2022)
- [Announcement] HGPI Endorsed “For the Health of People and Planet: Priorities for a Healthy COP28” (November 30, 2023)
- [Policy Recommendations] Furthering the Development of Precision Cancer Medicine —Proposals for Effective Policy Changes Based on Key Characteristics of Precision Medicine in Cancer Treatment— (September 20, 2022)
- [Activity Report] HGPI Submits Requests for the G7 Hiroshima Summit to the G7 Sous-Sherpa (December 23, 2022)
- [Urgent Recommendations] The Kidney Disease Control Promotion Project – Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration: Recommendations for Current Issues and Topics in Kidney Disease Control (May 11, 2022)
- [Policy Recommendations] Coming Together to Protect and Foster: Promoting Innovative and Sustainable Planetary Health in the Asia-Pacific Region to Build Resilient Health Systems (November 29, 2023)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
Featured Posts
-
2023-10-31
[Registration Open] Online Public Symposium “Dementia Risk Reduction: How Society Should Face the Individualization of Risk” (December 12, 2023)
-
2023-12-03
[Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
-
2023-12-04
[Registration Open] (Webinar) The 122nd HGPI Seminar: Keeping Pace with Growing Diversity of Health Information in Health Communication (December 19, 2023)
-
2023-12-05
[Policy Recommendations] Recommendation: Suggestions for Building a Resilient and Greener Health Care System Considering Sustainability and Environmental Concerns in the Revision of Medical, Nursing Care, and Disability Welfare Service Fees (December 6, 2023)
-
2023-12-05
[Registration Open] Online Global Expert Meeting: Considering Participation Among People Living with Dementia in the Formulation of National Dementia Strategies and in Policy Making Processes (January 22, 2024)